Splenomegaly with platelet sequestration
Increased platelet destruction by an immune mechanism; can occur as a result of:
Heparin-induced thrombocytopenia (HIT)
Idiopathic or immune thrombocytopenic purpura (ITP)
Drug (other than heparin)-induced thrombocytopenia
Post-transfusion purpura (PTP)
Increased platelet destruction by non-immune mechanisms, as caused by:
Hemolytic uremic syndrome (HUS)
Thrombotic thrombocytopenic purpura (TTP)
Decreased platelet production most often occurs after exposure to drugs (e.g., chemotherapeutic agents) that suppress synthesis of new platelets or by infiltration of the marrow by tumor or other structures.
Suggested Additional Lab Testing
Platelet count establishes presence or absence of thrombocytopenia; 100,000 functional platelets/µL is usually considered adequate for any challenge to hemostasis.
Workup for DIC:
D-dimer or FDP
Peripheral blood smear to check for schistocytes
Test for HIT:
Most often available is ELISA for antibody to platelet factor 4/heparin complex
ITP is a diagnosis of exclusion.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Counseling Patients on Oral Chemotherapy
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Patients and Caregivers Worry About Cost of Cancer Care
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Report From Childhood Cancer Survivor Study Identifies Long-Term Risks for VTE
- Opioid Shortage Influences How Cancer-Related Pain Is Managed by Inpatient Palliative Care Team
- Tumor Lysis Syndrome, Renal Failure Complicate Elotuzumab Therapy for Multiple Myeloma
- How to Help Patients at the End of Life and Their Loved Ones During the Holidays
- Real-World Prevalence of AEs With Immune Checkpoint Inhibitors for NSCLC Higher Than Reported in Trials
- Disparities Seen in Goals-of-Care Discussions With Minority vs Nonminority Patients
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|